Gilead Sciences Dividends Paid Growth & History (GILD)
Gilead Sciences paid $4.00B in dividends during fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual dividends paid history
| Fiscal year | Period ended | Dividends paid | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.00B | $85.0M | +2.17% |
| 2024 | 2024-12-31 | $3.92B | $109.0M | +2.86% |
| 2023 | 2023-12-31 | $3.81B | $100.0M | +2.70% |
| 2022 | 2022-12-31 | $3.71B | $104.0M | +2.88% |
| 2021 | 2021-12-31 | $3.60B | $156.0M | +4.52% |
| 2020 | 2020-12-31 | $3.45B | $227.0M | +7.05% |
| 2019 | 2019-12-31 | $3.22B | $251.0M | +8.45% |
| 2018 | 2018-12-31 | $2.97B | $240.0M | +8.79% |
| 2017 | 2017-12-31 | $2.73B | $276.0M | +11.24% |
| 2016 | 2016-12-31 | $2.46B | $581.0M | +31.00% |
| 2015 | 2015-12-31 | $1.87B | $1.87B | — |
| 2014 | 2014-12-31 | $0 | $0 | — |
| 2013 | 2013-12-31 | $0 | — | — |
Gilead Sciences quarterly dividends paid
| Fiscal quarter | Period ended | Dividends paid | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.03B | $35.0M | +3.52% |
| Q1 2026 | 2026-03-31 | $1.04B | $30.0M | +2.97% |
| Q4 2025 | 2025-12-31 | $994.0M | $21.0M | +2.16% |
| Q3 2025 | 2025-09-30 | $1.00B | $22.0M | +2.24% |
| Q2 2025 | 2025-06-30 | $994.0M | $22.0M | +2.26% |
| Q1 2025 | 2025-03-31 | $1.01B | $20.0M | +2.02% |
| Q4 2024 | 2024-12-31 | $973.0M | $30.0M | +3.18% |
| Q3 2024 | 2024-09-30 | $983.0M | $30.0M | +3.15% |
| Q2 2024 | 2024-06-30 | $972.0M | $28.0M | +2.97% |
| Q1 2024 | 2024-03-31 | $990.0M | $21.0M | +2.17% |
| Q4 2023 | 2023-12-31 | $943.0M | $28.0M | +3.06% |
| Q3 2023 | 2023-09-30 | $953.0M | $24.0M | +2.58% |
| Q2 2023 | 2023-06-30 | $944.0M | $24.0M | +2.61% |
| Q1 2023 | 2023-03-31 | $969.0M | $24.0M | +2.54% |
| Q4 2022 | 2022-12-31 | $915.0M | $21.0M | +2.35% |
| Q3 2022 | 2022-09-30 | $929.0M | $29.0M | +3.22% |
| Q2 2022 | 2022-06-30 | $920.0M | $26.0M | +2.91% |
| Q1 2022 · Mar 31 | 2022-03-31 | $945.0M | $28.0M | +3.05% |
| Q4 2021 | 2021-12-31 | $894.0M | $36.0M | +4.20% |
| Q3 2021 | 2021-09-30 | $900.0M | $39.0M | +4.53% |
| Q2 2021 | 2021-06-30 | $894.0M | $38.0M | +4.44% |
| Q1 2021 | 2021-03-31 | $917.0M | $43.0M | +4.92% |
| Q4 2020 | 2020-12-31 | $858.0M | $57.0M | +7.12% |
| Q3 2020 | 2020-09-30 | $861.0M | $57.0M | +7.09% |
| Q2 2020 | 2020-06-30 | $856.0M | $56.0M | +7.00% |
| Q1 2020 | 2020-03-31 | $874.0M | $57.0M | +6.98% |
| Q4 2019 | 2019-12-31 | $801.0M | $65.0M | +8.83% |
| Q3 2019 | 2019-09-30 | $804.0M | $62.0M | +8.36% |
| Q2 2019 | 2019-06-30 | $800.0M | $60.0M | +8.11% |
| Q1 2019 | 2019-03-31 | $817.0M | $64.0M | +8.50% |
| Q4 2018 | 2018-12-31 | $736.0M | $54.0M | +7.92% |
| Q3 2018 | 2018-09-30 | $742.0M | $60.0M | +8.80% |
| Q2 2018 | 2018-06-30 | $740.0M | $60.0M | +8.82% |
| Q1 2018 | 2018-03-31 | $753.0M | $66.0M | +9.61% |
| Q4 2017 | 2017-12-31 | $682.0M | $63.0M | +10.18% |
| Q3 2017 | 2017-09-30 | $682.0M | $59.0M | +9.47% |
| Q2 2017 | 2017-06-30 | $680.0M | $54.0M | +8.63% |
| Q1 2017 | 2017-03-31 | $687.0M | $100.0M | +17.04% |
| Q4 2016 | 2016-12-31 | $619.0M | $5.0M | +0.81% |
| Q3 2016 | 2016-09-30 | $623.0M | −$4.0M | −0.64% |
| Q2 2016 | 2016-06-30 | $626.0M | −$7.0M | −1.11% |
| Q1 2016 | 2016-03-31 | $587.0M | $587.0M | — |
| Q4 2015 | 2015-12-31 | $614.0M | — | — |
| Q3 2015 | 2015-09-30 | $627.0M | $627.0M | — |
| Q2 2015 | 2015-06-30 | $633.0M | — | — |
| Q1 2015 | 2015-03-31 | $0 | — | — |
| Q3 2014 | 2014-09-30 | $0 | — | — |
Gilead Sciences dividends paid trends
Over the last five fiscal years, Gilead Sciences's dividends paid increased from $3.45B to $4.00B, a change of $554.0M. The latest reported quarter, Q2 2026, shows $1.03B.
What dividends paid mean
Dividends paid are cash distributions made to shareholders. The history shows the company’s aggregate cash outflow for dividends, not the dividend per share, dividend yield, or the date an investor receives a payment.
Reported cash dividends paid
TickerStat standardizes cash dividends paid to common or ordinary shareholders from official cash-flow filings. Reported zero-dividend periods remain zero and are not treated as missing data. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...